Clustering data with hclust algorithm for Effects of LGG on current drinkers gut metabolism (Study ST000321)

Reversed phase NEGATIVE ION MODE (Analysis AN000511)
MetaboliteStructureF1F2F3F4
Ceramide (d43:1)ME1143180.921.301.370.26
Ceramide (d44:1)ME1143190.991.301.320.33
LPE (16:0)ME1143381.230.081.780.11
LPC (16:0)ME1143341.120.251.730.23
FA (22:1) (erucic acid)ME1143271.250.281.600.20
LPC (18:0)ME1143351.250.211.650.18
PE (p-38:5) or PE (o-38:6)ME1143791.440.141.060.07
PE (p-34:1) or PE (o-34:2)ME1143711.360.141.350.04
PE (p-36:1) or PE (o-36:2)ME1143731.270.131.240.04
PE (p-36:2) or PE (o-36:3)ME1143741.310.191.170.09
FA (20:1) (eicosenoic acid)ME1143231.450.151.460.21
Ceramide (d34:0)ME1143041.440.141.500.15
Ceramide (d34:1)ME1143051.460.161.480.15
GlcCer(d14:1(4E)/20:0(2OH))ME1143331.620.101.260.14
FA (18:3) (linolenic acid)ME1143221.590.101.330.22
FA (20:3) (ho[Mo-ga[M[Ma-linolenic acid)ME1143241.630.031.330.21
FA (20:5) (eicosapentaenoic acid)ME1143251.220.311.500.38
LPC (18:1)ME1143361.160.191.480.36
FA (17:0) [Margaric acid)ME1143211.420.271.300.40
PC (36:3)ME1143501.450.221.300.40
Ceramide (d33:1)ME1143031.350.231.440.33
FA (22:6) (docosahexaenoic acid)ME1143281.360.241.440.30
Ceramide (d32:1)ME1143021.280.331.300.36
Ceramide (d36:1)ME1143081.340.321.400.35
Ceramide (d40:0)_2ME1143111.350.321.360.38
PC (36:4)ME1143511.370.311.340.39
Ceramide (d42:0)_1ME1143151.470.491.220.30
FA (14:0) [Myristic acid)ME1143201.640.311.210.18
Ceramide (d34:2)_2ME1143071.08NA1.340.26
PC (p-36:3) or PC (o-36:4)ME1143601.07NA1.080.54
PE (p-40:7) or PE (o-40:8)ME1143811.240.281.010.26
PE (p-34:2) or PE (o-34:3)ME1143721.080.271.00NA
PE (p-36:4) or PE (o-36:5)ME1143751.150.041.060.01
PE (p-38:4) or PE (o-38:5)ME1143780.99NA1.02NA
PC (p-36:4) or PC (o-36:5)ME1143611.06NA0.94NA
PE (p-40:6) or PE (o-40:7)ME1143801.07NA0.93NA
PC (35:1)ME1143471.030.221.081.16
Ceramide (d40:2)ME1143130.801.021.191.06
LPC (18:2)ME1143370.960.691.161.04
PC (38:5)ME1143551.220.710.990.64
PC (p-36:1) or PC (o-36:2)ME1143591.200.641.100.59
PE (36:2)ME1143651.100.701.140.84
PE (38:2)ME1143681.090.781.030.70
Ceramide (d40:1)ME1143121.110.821.140.70
Ceramide (d42:2)ME1143171.180.771.090.70
Ceramide (d34:2)_1ME1143061.051.111.020.82
Ceramide (d41:1)ME1143141.021.081.160.60
PE (p-36:5) or PE (o-36:6)ME1143761.090.811.280.43
FA (22:0) (behenic acid)ME1143261.140.661.460.31
FA (26:0) (cerotic acid)ME1143311.200.641.450.27
FA (24:0) (lignoceric acid)ME1143291.170.741.400.31
FA (28:0) [Montanic acid)ME1143321.210.811.350.28
PC (p-40:1) or PC (o-40:2)ME1143621.180.551.100.41
PC (36:2)ME1143491.220.581.310.49
Ceramide (d40:0)_1ME1143101.180.481.340.38
FA (24:1) (nervonic acid)ME1143301.220.431.380.48
PE (34:1)ME1143631.470.141.170.62
PE (36:4)ME1143671.570.160.940.59
PC (32:2)ME1143431.190.321.000.66
PE (38:4)_1ME1143691.220.420.960.50
PE (36:3)ME1143661.320.411.080.79
PE (38:4)_2ME1143701.400.531.060.63
SM (d34:1)ME1143831.240.561.160.70
PC (38:4)ME1143541.260.471.120.67
SM (d34:0)ME1143821.290.491.070.59
PE (36:1)ME1143641.100.361.190.81
PC (p-34:0) or PC (o-34:1)ME1143571.120.261.120.78
PC (38:3)ME1143531.180.361.090.81
PC (p-34:1) or PC (o-34:2)ME1143581.060.361.070.81
PC (32:1)ME1143421.280.151.230.70
PC (34:3)ME1143461.160.201.270.63
PC (34:1)ME1143441.250.251.340.62
PC (36:1)ME1143481.250.241.290.69
PC (34:2)ME1143451.190.401.300.66
Ceramide (d38:1)ME1143091.180.441.230.63
PC (32:0)ME1143411.160.451.270.67
Ceramide (d42:0)_2ME1143161.310.391.200.58
PE (p-38:3) or PE (o-38:4)ME1143771.280.261.130.65
LPE (18:2)ME1143390.820.580.921.82
PC (38:6)ME1143560.860.920.961.49
PC (36:5)ME1143520.761.400.771.66
SM (d42:1)ME1143851.121.050.542.00
LPE (20:4)ME1143400.230.750.303.01
SM (d40:1)ME1143840.831.030.772.65
SM (d42:2)ME1143860.651.390.612.55

Factors:

F1Treatment:Alcoholic cirrhosis infusion
F2Treatment:Germ Free Control
F3Treatment:LGG Treated
F4Treatment:Normal Human Infusion
Data matrix
  logo